Axitinib in Metastatic Renal Cell Carcinoma
نویسندگان
چکیده
منابع مشابه
Axitinib in Metastatic Renal Cell Carcinoma
Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar concentrations distinguishes it as a potent tyrosine kinase inhibitor, with increased selectivity fo...
متن کاملAxitinib in sequential therapy in metastatic renal cell carcinoma
Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived grow...
متن کاملAxitinib in metastatic renal cell carcinoma: single center experience
AIM OF THE STUDY Due to the emergence of new therapeutic opportunities in the second-line treatment of metastatic renal cell carcinoma, the choice of the appropriate medication requires consideration. Making the selection one should take into account the likelihood of response, the probability of toxicity, properties of the drug and the clinical characteristics of the patient. Aim of the work w...
متن کاملAxitinib for the Management of Metastatic Renal Cell Carcinoma
In recent years, targeted agents have changed the treatment landscape for patients with advanced renal cell carcinoma (RCC), greatly improving treatment outcomes. Several targeted agents are now licensed for the treatment of metastatic RCC (mRCC), and a number of new agents are under investigation. Axitinib, a small molecule indazole derivative is an oral, potent multitargeted tyrosine kinase r...
متن کاملAxitinib: Newly Approved for Renal Cell Carcinoma
4503 (Rini et al.) from the 2012 ASCO annual meeting, as well as information on specialty pharmacies and patient assistance. SEE PAGE XXX SEE PAGE 298 erythrodysesthesia (hand-foot syndrome), but this was in a heavily pretreated population. The question of whether these side effects will remain as pronounced in a first-line setting is still unanswered. Of equal importance is whether or not the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biologics in Therapy
سال: 2012
ISSN: 2190-9164
DOI: 10.1007/s13554-012-0005-2